HUAWEI DESIGN
833427
HST
870726
Hangzhou Huasu Technology
301157
Suzhou Alton Electrical & Mechanical Industry
301187
Shanghai Kaytune Industrial
301001
CN Stock MarketDetailed Quotes
300966 Hubei Goto Biopharm
- 15.61
- -0.11-0.70%
Market Closed Jan 8 15:00 CST
1.80BMarket Cap-129.01P/E (TTM)
16.02High15.23Low17.67KlotVolume15.71Open15.72Pre Close27.66MTurnover2.35%Turnover Ratio78.05P/E (Static)115.28MShares24.5852wk High2.14P/B1.17BFloat Cap12.0152wk Low18.86Limit Up75.13MShs Float79.83Historical High12.58Limit Down5.03%Amplitude12.01Historical Low0.02Dividend TTM15.65Avg Price8.80KlotAsk0.10%Div YieldTTM100Lot Size8.33KlotBid
Hubei Goto Biopharm News
Hubei Goto Biopharm: Announcement regarding cumulative new loans exceeding 20% of net assets at the end of the previous year.
Mutual Pharmaceutical: Hubei Gonghe Pharmaceutical Co., Ltd. Entities and Mutual Debt Transfers 2023 Annual Tracking Rating Report
Kyodo Pharmaceutical: Additional Legal Opinions from 3 Law Firms (2) (Financial Data Update for the Semi-Annual Year of 2022)
Kyodo Pharmaceutical: 2 Accountants' Response to the Audit Inquiry Letter (Exempted Edition) (2022 Semi-Annual Financial Data Update)
Kyodo Pharmaceutical: 2 Accountants' Response to the Enquiry Letter on the Second Round of Audit (2022 Semi-Annual Financial Data Update)
Mutual Pharmaceuticals: 1 Responses from issuers and sponsors to the review enquiry letter (revised version of the exempted version) (Financial data update for the half year 2022)
Mutual Pharmaceuticals: 1 Responses from issuers and sponsors to the second round of review enquiry letter (revised draft) (Financial data update for the half year 2022)
Mutual Pharmaceutical: Issuer's and sponsor's response report to the second round of review and enquiry letter on the application of Hubei Common Pharmaceutical Co., Ltd. to issue convertible corporate bonds to unspecified targets (revised draft) (2022 sem
Mutual Pharmaceutical: Issuer and Sponsor's Response Report to the Audit Enquiry Letter of Hubei Common Pharmaceutical Co., Ltd.'s Application for Issuance of Convertible Corporate Bonds to Unspecified Targets (Exempted Revised Draft) (Updated Financial Da
Kyodo Pharmaceutical: Prompt Notice on Responses to Audit Inquiries on Applications for Issuance of Convertible Corporate Bonds to Unspecified Targets and Financial Data Updates for Application Documents such as Prospectus
Kyodo Pharmaceutical Co., Ltd.: 1-1 Prospectus (Application Draft)
Kyodo Pharmaceutical: 3-3 Listing Sponsorship Letter (Application Draft)
Kyodo Pharmaceutical: 3-1 Securities Issuance Sponsorship Letter (Declaration Draft)
Mutual Pharmaceutical: Issuer's and sponsor's response report to the second round of review and inquiry letter on the application of Hubei Common Pharmaceutical Co., Ltd. to issue convertible corporate bonds to unspecified targets (revised draft)
Kyodo Pharmaceutical: Indicative Notice on Response to the Second Audit Inquiry Letter on the Application for Issuance of Convertible Corporate Bonds to Unspecified Targets (Revised Draft)
Mutual Pharmaceuticals: 1 Issuer's and Sponsors' Responses to the Second Round of Review Enquiry Letter (Revised Draft)
Kyodo Pharmaceutical: 2 Accountants' Response to the Second Audit Enquiry Letter
Kyodo Pharmaceutical: 3-3 Listing Sponsorship Letter (Application Draft)
Kyodo Pharmaceutical: 3-1 Securities Issuance Sponsorship Letter (Declaration Draft)
Kyodo Pharmaceutical Co., Ltd.: 1-1 Prospectus (Application Draft)
